IMFINZI® (Durvalumab) with Bacillus Calmette-Guerin (BCG)

RR FDA Approvals
Urothelial Cancer (Bladder-Ureters-Renal-Pelvis)

The FDA on May 28, 2026, approved IMFINZI® with BCG for the treatment of adult patients with BCG-naïve, high-risk Non-Muscle Invasive Bladder Cancer (NMIBC). IMFINZI® is a product of AstraZeneca.

Related Posts: